API | triflusal

triflusal Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a derivative of acetylsalicylic acid in which a hydrogen atom on the benzene ring has been replaced by a trifluoromethyl group. Trade names include Disgren, Grendis, Aflen and Triflux. ^Wikipedia

Chemistry

SMILES: CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
InChIKey: RMWVZGDJPAKBDE-UHFFFAOYSA-N
Mol. Mass: 248.16
ALogP: 2.33 Partition coefficient
ChEMBL Molecule:
triflusal

More Chemistry

Pharmacology

Mechanism of Action:
- Prostaglandin G/H synthase 1 (Homo sapiens) ^UniProt
- Prostaglandin G/H synthase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-acetoxy-4-trifluoromethylbenzoic acid | 2- (acetyloxy)-4-(trifluoromethyl)benzoic acid | disgren | triflusal

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (1)

Stroke

Experimental Indications - Clinical Trial Phases 1-4 (6)

Cerebral Infarction (Phase 4)

Healthy Volunteers (Phase 2)

Insulin Resistance (Phase 2)

Muscle Spasticity (Phase 4)

Pain ()

Thrombosis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue